Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia

BACKGROUND: Thrombocytopenia in patients with myelodysplastic syndrome (MDS) is associated with shortened survival and an increased risk of evolution to acute myeloid leukemia (AML). In this study, the authors evaluated the efficacy of romiplostim in patients who had thrombocytopenia with low-risk/i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Giagounidis, Aristoteles, Mufti, Ghulam J, Fenaux, Pierre, Sekeres, Mikkael A, Szer, Jeffrey, Platzbecker, Uwe, Kuendgen, Andrea, Gaidano, Gianluca, Wiktor-Jedrzejczak, Wieslaw, Hu, Kuolung, Woodard, Paul, Yang, Allen S, Kantarjian, Hagop M
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4298760/
https://ncbi.nlm.nih.gov/pubmed/24706489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28663
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados